Alpine Immune Sciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alpine Immune Sciences Inc.
Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials
VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.
Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
Combined AbbVie/Allergan Makes Earnings Debut
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies
The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.
- Large Molecule
- Other Names / Subsidiaries
- N30 Pharmaceuticals, Inc.
- Nivalis Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.